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Abstract
Following traumatic brain injury, complex cerebral energy perturbations occur. Correlating with unfavourable outcome,
high brain extracellular lactate/pyruvate ratio suggests hypoxic metabolism and/or mitochondrial dysfunction. We inves-
tigated whether focal administration of succinate, a tricarboxylic acid cycle intermediate interacting directly with the
mitochondrial electron transport chain, could improve cerebral metabolism. Microdialysis perfused disodium 2,3-13C2
succinate (12mmol/L) for 24 h into nine sedated traumatic brain injury patients’ brains, with simultaneous microdialysate
collection for ISCUS analysis of energy metabolism biomarkers (nine patients) and nuclear magnetic resonance of
13C-labelled metabolites (six patients). Metabolites 2,3-13C2 malate and 2,3-
13C2 glutamine indicated tricarboxylic acid
cycle metabolism, and 2,3-13C2 lactate suggested tricarboxylic acid cycle spinout of pyruvate (by malic enzyme or
phosphoenolpyruvate carboxykinase and pyruvate kinase), then lactate dehydrogenase-mediated conversion to lactate.
Versus baseline, succinate perfusion significantly decreased lactate/pyruvate ratio (p¼ 0.015), mean difference 12%, due
to increased pyruvate concentration (þ17%); lactate changed little (3%); concentrations decreased for glutamate
(43%) (p¼ 0.018) and glucose (15%) (p¼ 0.038). Lower lactate/pyruvate ratio suggests better redox status: cytosolic
NADH recycled to NADþ by mitochondrial shuttles (malate-aspartate and/or glycerol 3-phosphate), diminishing lactate
dehydrogenase-mediated pyruvate-to-lactate conversion, and lowering glutamate. Glucose decrease suggests improved
utilisation. Direct tricarboxylic acid cycle supplementation with 2,3-13C2 succinate improved human traumatic brain
injury brain chemistry, indicated by biomarkers and 13C-labelling patterns in metabolites.
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Introduction
After traumatic brain injury (TBI), complex path-
ology follows, intertwining intracranial dynamics,
electrophysiological responses and cerebral metab-
olism.1–4 Despite modern advances, many TBI
survivors experience long-term disability. Better neu-
rocritical care requires better understanding of post-
injury brain pathophysiology. Early studies focussed
on ischaemia, nowadays minimised by protocol-
driven therapy maintaining adequate cerebral per-
fusion with intracranial pressure below a critical
threshold.5
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Despite seemingly adequate provision of metabolic
fuels and oxygen, the injured brain sometimes cannot
utilise them eﬃciently: termed ‘mitochondrial dysfunc-
tion’, the exact basis is not understood. One potentially
relevant process is the reduced Ca2þ uptake state after
TBI,6 which will depress the activities of several mito-
chondrial dehydrogenases,7 leading to suboptimal
mitochondrial metabolism. Mitochondria are the cells’
‘powerhouses’ performing high-yielding energy metab-
olism. Glycolysis in the cytoplasm produces pyruvate,
taken up by mitochondria and processed via the tri-
carboxylic acid (TCA) cycle, which interacts with the
mitochondrial electron transport chain (ETC; also
termed respiratory chain) driving ATP synthase. The
ETC requires molecular oxygen as terminal electron
acceptor. Correlating with unfavourable clinical out-
come, high brain extracellular lactate/pyruvate ratio
(LPR) suggests high glycolytic activity3: glucose con-
verted to pyruvate generating a low ATP yield, then
lactate dehydrogenase (LDH) converts pyruvate plus
NADH to lactate plus NADþ, allowing further
glycolysis.
Succinate is energetically important – a TCA cycle
intermediate and a direct contact between the TCA
cycle and the mitochondrial ETC. Succinate conversion
to fumarate in the TCA cycle is by ETC complex II
(succinate dehydrogenase (SDH)), on the mitochon-
drial inner membrane. Soluble mitochondrial enzymes
perform all the other TCA cycle steps; the NADH pro-
duced interacts with ETC complex I, then electron
transport runs sequentially (missing out complex II)
to Coenzyme Q (CoQ; also termed ubiquinone), com-
plex III, Cytochrome C and complex IV.8 Succinate,
contrastingly, misses out complex I, and electron trans-
port runs sequentially from complex II to CoQ, com-
plex III, Cytochrome C and complex IV with molecular
oxygen as terminal electron acceptor, culminating in
conversion of oxygen to water.8 Complexes I, III and
IV export protons across the mitochondrial inner mem-
brane creating a proton electrochemical potential gra-
dient, driving ATP synthesis at complex V (ATP
synthase), converting ADP to ATP.8
Succinate can support compromised mitochondria,
as it bypasses complex I that can be more vulnerable
to inhibition/damage than complexes II, III and IV.9
Optimization of residual energy-producing ability may
prevent the ATP level from dropping critically low initi-
ating cell death pathways. ‘Bypassing’ defective ETC
components sustained muscle ATP synthesis in a patient
with genetically defective complex III, using vitamins C
and K.10 In experimental sepsis (which involves energy
dysfunction), succinate infusion prevented fall in liver
ATP content,11 and prolonged survival.12
Succinate uptake is via the SLC13 family of Naþ-
coupled di-carboxylate and tri-carboxylate
transporters.13–15 SLC13 occur widely, including
in brain, astrocytes and neurons where succinate
uptake and metabolism were also shown using radio-
labelling.16–18 Additionally, nonspeciﬁc uptake might
occur in any cells with increased plasma membrane
permeability. Succinate is metabolised to fumarate
by SDH, ETC complex II on the inner mitochondrial
membrane. SDH occurs at high concentrations only
within mitochondria.19 Hence, appearance of metabol-
ites with characteristic 13C nuclear magnetic resonance
(NMR) doublet signals will clearly indicate uptake
and mitochondrial metabolism of 2,3-13C2 succinate.
For a schematic of labelling via the TCA cycle, see
Figure 1. In the TCA cycle, succinate’s metabolite
fumarate is converted to malate and then to oxaloa-
cetate (OAA) that can proceed in the TCA cycle to
alpha-ketoglutarate, and then spin out (via glutamate)
to glutamine. Also, OAA can spin out aspartate,
which can exit mitochondria (via the glutamate/
aspartate carrier) via the malate-aspartate shuttle
mechanism.20 In the cytosol, aspartate is converted
to OAA and thence to malate, which can re-enter
mitochondria (via the malate/alpha-ketoglutarate car-
rier) and/or may emerge from the TCA cycle via this
pathway.
We tested the hypothesis that 2,3-13C2 succinate (dis-
odium salt) administered by cerebral microdialysis
would fuel and enhance the TCA cycle and improve
cerebral metabolism focally in TBI patients. We ana-
lysed metabolites using NMR of the emerging
microdialysates. We successfully used 13C-labelled
microdialysis (Figure 2) previously with diﬀerent sub-
strates.21–23 Microdialysates were also analysed for con-
ventional clinical biomarkers of brain chemistry,3 at
baseline and during succinate perfusion. Double
13C-labelling proves unambiguously that substrate mol-
ecules crossed from the perfusate into the brain extra-
cellular space, entered cells and were metabolised,
exported into the extracellular ﬂuid, and recovered by
the microdialysis catheter.
Patients and methods
Patients
The protocol was approved by the National Research
Ethics Service (NRES) Committee East of England –
Cambridge Central (REC Reference No. 11/EE/0463).
Written, informed consent was obtained from the next
of kin for all subjects. The study was carried out in
conformation with the spirit and the letter of the
Declaration of Helsinki 1975 (and revised in 1983).
Patients (age over 16 years) with severe TBI, deﬁned
as cranial trauma with consistent CT scan ﬁndings
and a post-resuscitation Glasgow Coma Scale 8
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were recruited. Patients were treated according to local
TBI management protocols, including endotracheal
intubation, ventilation, sedation, muscular paralysis
and maintenance of blood sugar (serum glucose) con-
centration within the target range 4–7mmol/L.5
Microdialysis technique
CMA 71 microdialysis catheters (membrane 10mm,
cut-oﬀ 100 kDa) (M Dialysis AB, Stockholm,
Sweden) were placed via a triple lumen cranial
access device (Technicam, Newton Abbot, UK) into
frontal lobe. For patients with diﬀuse injury, the right
frontal region was chosen. If one hemisphere was
more injured than the other, the more injured hemi-
sphere was monitored. Catheters were placed neither
into, nor adjacent to, lesions identiﬁed on neuroima-
ging, e.g. contusions. Licox brain tissue oxygen con-
centration (PbtO2) monitoring probes (Integra
LifeSciences Corporation, Plainsboro, NJ) were
Figure 1. Schematic of metabolism of 2,3-13C2 succinate via the TCA cycle and spin-out pathways. Blue-filled circles indicate
13C
atoms. Red rectangular outlines indicate metabolites detected by 13C NMR in microdialysates. For further details, see Results and
Discussion sections. ME: malic enzyme; PC: pyruvate carboxylase; PDH: pyruvate dehydrogenase; PEPCK: phosphoenolpyruvate
carboxykinase; PK: pyruvate kinase.
Figure 2. Schematic of 13C-labelled microdialysis. Microdialysis
is used both to deliver 13C-labelled succinate focally into the
brain extracellular space and simultaneously collect those
metabolite molecules that exit from the cells.
Source: Adapted from Carpenter et al.23 2014 The Authors.
Published by Elsevier B.V. Open access under a CC–BY licence.
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inserted alongside the microdialysis catheters via the
same cranial access device.
Catheters were perfused with CNS Perfusion Fluid
(M Dialysis AB), composed of NaCl (147mmol/L),
KCl (2.7mmol/L), CaCl2 (1.2mmol/L) and MgCl2
(0.85mmol/L) in water supplemented with 12mmol/L
disodium 2,3-13C2 succinate (isotopic enrichment 99%,
chemical purity 99%) from Cambridge Isotope
Laboratories, Inc (Tewksbury, MA) and formulated
in CNS perfusion ﬂuid by the Manufacturing Unit,
Department of Pharmacy, Ipswich Hospital NHS
Trust (Ipswich, UK), who then tested the formulations
for purity, sterility, freedom from endotoxins and
absence of pyrogenicity, before release for use in
patients. The 12mmol/L concentration was chosen for
2,3-13C2 succinate, because it represents the same
number of carbon atoms (12mmol/L 4 carbon
atoms per succinate molecule¼ 48mmol of carbon
atoms/L) equivalent to glucose at the upper end24 of
its microdialysate concentration range (8mmol/L 6
carbon atoms per glucose molecule¼ 48mmol of
carbon atoms/L). Glucose concentrations of 8mmol/L
in microdialysates are rare; we deliberately chose this
high level as being above the more frequently seen
levels (which are usually under 5mmol/L) to ensure
that there was no substrate limitation and we could
augment the TCA cycle eﬀectively. Moreover, with
microdialysis delivery of a substrate, a diﬀusion gradi-
ent will exist such that the tissue levels achieved will not
exceed the perfusate concentration.
Microdialysate collection vials were changed and
analysed hourly on a bedside ISCUS analyser (M
Dialysis AB) employing enzymatic colorimetric assays
for glucose, lactate, pyruvate, glutamate and glycerol,
during perfusion with 2,3-13C2-succinate, and for a
baseline perfusion period with unsupplemented CNS
perfusion ﬂuid. The latter was either before or after
the 2,3-13C2 succinate perfusion period, with a 2 h
exclusion margin applied to the ISCUS data analysis
to allow for run-in or wash-out. By testing standard
solutions of the ﬁve ISCUS analytes at concentrations
representative of those in vivo, in CNS-perfusion ﬂuid,
with and without disodium succinate standard
(12mmol/L), we established that succinate did not
interfere with the ISCUS enzymatic colorimetric
chemistry.
NMR analysis
Brain microdialysate samples analysed on the ISCUS at
the bedside were then stored at 4C (or –80C if storage
for longer than a few days was necessary) prior to
NMR analysis. Microdialysate samples from a 24-h
period during 2,3-13C2 succinate perfusion were
pooled for each individual patient, due to sensitivity
limitations of NMR equipment (see ‘Limitations’ sub-
section of the Discussion for further explanation). For
NMR analysis, 20 mL of deuterium oxide (D2O) and
50 mL internal reference standard from a stock solution
of 24.0mmol/L 3 -(trimethylsilyl)-1-propanesulfonic
acid sodium salt (also termed 2,2-dimethyl-2-silapen-
tane-5-sulfonate sodium salt or 4,4-dimethyl-4-silapen-
tane-1-sulfonate sodium salt; DSS) (Sigma-Aldrich,
Gillingham, UK) in CNS perfusion ﬂuid was added
to 180mL of the pooled microdialysate sample, then
transferred into 3mm NMR tubes (Hilgenberg
GmbH, Malsfeld, Germany).
13C and 1H NMR spectra were acquired on a Bruker
Avance III HD 500MHz spectrometer (Bruker BioSpin
GmbH, Karlsruhe, Germany) with a dual 1H/13C
cryoprobe (CP DUL500C/H, Bruker BioSpin
GmbH), and TopSpin software (Bruker GmbH). For
further details of NMR measurements, see Jalloh
et al.22 Direct-observe 13C NMR is a wide-ranging
screening technology not requiring operators to make
prior decisions of what to seek. NMR does not involve
physical contact with the sample, which is enclosed in
an individual glass tube throughout measurement, elim-
inating cross-contamination or sample carry-over.
Fractional enrichment (%) is deﬁned as 100 [13C]/
([13C]þ [12C]) where square brackets indicate concen-
trations. [13C] was determined from the 13C NMR spec-
tra and [12C] for lactate from the 1H spectra, using the
calibration principles described previously.22 Total glu-
tamine concentration (12C and 13C) was quantiﬁed by
reverse-phase high-performance liquid chromatog-
raphy.25 The natural abundance of 13C is 1.1% of all
carbon atoms, and 13C results presented for lactate and
glutamine were expressed after subtracting this natural
background from the 13C singlet NMR signals. 13C
doublet NMR signals for lactate and glutamine were
not background-subtracted, because the probability of
two natural endogenous 13C atoms being next to each
other is 1.1% 1.1%¼ 0.01%.
Statistical analysis
Changes between baseline and succinate perfusion per-
iods were assessed using Wilcoxon signed rank test
(StatView version 5, SAS Institute, Cary, NC), with
p< 0.05 for signiﬁcance. The corresponding eﬀect
sizes (matched-pairs rank-biserial correlation r) were
calculated by the method described by Kerby.26
Results
Demography
Nine severe TBI patients (seven male, two female) aged
18–60 years (median 47 years) were studied using
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2,3-13C2 succinate (disodium salt; 12mmol/L) perfused
via the microdialysis catheter, and for a baseline period
with plain unsupplemented perfusion ﬂuid (without
2,3-13C2 succinate). Table 1 describes demography,
catheter positions and PbtO2 measured alongside
microdialysis in 7/9 of the patients. Median PbtO2
measurements were above 20mmHg in ﬁve patients
and above 15mmHg in the other two patients.
Bedside analysis results
Microdialysate measurements (ISCUS analyser) of glu-
cose, lactate, pyruvate, glutamate, glycerol and LPR
are shown in Figure 3 and Supplementary Table 1.
The ISCUS cannot measure other species. ISCUS
measurements were acquired for the nine TBI patients
for a 24-h period while the microdialysis catheter was
perfused with plain unsupplemented CNS perfusion
ﬂuid directly before or after a 24-h perfusion period
with 2,3-13C2 succinate (12mmol/L). Each data-point
shown is the median concentration for that patient
during the relevant 24 h period (24 1 h vials). Paired
(baseline vs. succinate) data were available in all nine
patients for glucose, lactate, pyruvate and LPR, and in
7/9 patients for glutamate and 6/9 patients for glycerol.
We chose pair-wise statistics (Wilcoxon signed rank
test) for comparing baseline vs. succinate perfusion,
so that each patient was represented by a pair of
data-points preserving data connectivity within each
patient. This avoided risk of bias, rather than pooling
data and using unpaired statistics that would have
incorrectly assumed too many degrees of freedom
and over-estimated signiﬁcance. In addition to
Wilcoxon signed rank test signiﬁcance p values, we
also report eﬀect size (matched-pairs rank-biserial cor-
relation r).26
Versus baseline, succinate perfusion signiﬁcantly
decreased the LPR (p¼ 0.015; eﬀect size r¼ 0.91),
decreasing in 8/9 patients and increasing in 1/9, mean
diﬀerence 12%. This was due to increased pyruvate
concentration, increasing in 7/9 and decreasing in 2/9,
mean diﬀerenceþ 17%, missing signiﬁcance (p¼ 0.11;
eﬀect size r¼ 0.60). Lactate concentration changed
insigniﬁcantly (p¼ 0.86; eﬀect size r¼ 0.07), increasing
in 4/9 and decreasing in 5/9, mean diﬀerence 3%.
Glycerol concentration change did not reach signiﬁ-
cance (p¼ 0.075; eﬀect size r¼ 0.81), increasing in 5/6
and decreasing in 1/6. Glutamate concentration
decreased signiﬁcantly (p¼ 0.018; eﬀect size r¼ 1.00)
in 7/7, mean diﬀerence43%. Glucose also decreased
signiﬁcantly (p¼ 0.038; eﬀect size r¼ 0.78), decreasing
in 7/9 and increasing in 2/9, mean diﬀerence 15%.
The greatest decreases in microdialysate glucose were
in the four individuals (ranging from 22.9% to
31.7%) whose microdialysate glucose baseline con-
centration was above 3mmol/L. In the two patients
with the highest baseline LPRs of 31.3 and 26.8, these
decreased to 21.5 and 23.3, respectively, during succin-
ate perfusion, thus bringing them below 25, regarded as
a crucial threshold.3,27 These results are graphed in
Figure 3 and tabulated in Supplementary Table 1.
Changes in ISCUS data are modest rather than
extreme, as we micro-dosed a focal region of brain.
While we cannot rule out some spontaneous changes
in brain chemistry, a much larger unsupplemented
microdialysis TBI study showed no clear longitudinal
Table 1. Patient demography.
TBI
Patient i.d.
number
Age
(years) Sex
Injury
mechanism
GCS at
scene/15
2,3-13C2 succinate
perfusion
period start time
(hours from injury)
Marshall
grade
(admission)
Catheter
locationa
CT
description
PbtO2 at baseline
and during 2,3-13C2
succinate perfusion
(mmHg)
1 56 F Fall 10 26.0 6a L frontal EDH, contusions 25.3, 31.1
2 52 M RTC 4 121.3 3 R frontal DAI –
3 18 M RTC 8 41.9 3 R frontal DAI, contusions 21.8, 20.4
4 47 M RTC 8 36.9 2b R frontal DAI, contusions 19.9, 27.4
5 41 F Fall 3 67.5 6b R frontal R ASDH –, 35.7
6 20 M Assault 14 83.0 3 R frontal DAI, contusions –, 15.8
7 60 M Fall 11 103.9 2d R frontal DAI, contusions 18.6, 17.9
8 47 M RTC 9 160.4 2b R frontal DAI –
9 46 M RTC 6 79.5 3 R frontal L ASDH 34.9, 34.9
M: male; F: female; RTC: road traffic collision; GCS: Glasgow Coma Scale score; L: left; R: right; EDH: extradural haematoma; DAI: diffuse axonal injury;
ASDH: acute subdural haematoma; PbtO2: brain tissue oxygen tension (median values; – not measured).
aCatheter (microdialysis) location: for patients
with a diffuse injury, the right frontal region was chosen; if there was greater injury to one hemisphere rather than the other, the side with the greater
burden of injury was monitored. Catheters were inserted via a cranial access device and were placed neither into nor adjacent to lesions (such as
contusions) identified on neuroimaging. PbtO2 monitoring probes were inserted alongside the microdialysis catheters via the same cranial access
device.
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trends.24 Comparing changes within patient (baseline
vs. succinate supplementation) was preferable to com-
paring pooled data for the supplemented patients with
a separate control unsupplemented group, as is well
known that there is much variation between patients
for ISCUS data. Using each patient as his/her own
control was logical in this small group.
NMR results
NMR analysis of brain microdialysates was performed
for six TBI patients who received 2,3-13C2 succinate
microdialysis perfusion (Figure 4 illustrates examples).
To achieve this, 24 1 h microdialysate vials were
pooled for each patient, due to sensitivity limitations
of our NMR equipment (see ‘Limitations’ subsection of
the Discussion for further explanation). It was there-
fore not possible for us to obtain time-course data by
NMR. All six patients showed a strong signal at
36.9 ppm for succinate C2 and C3 (2,3-13C2 succinate).
This is a singlet because succinate is a symmetrical
molecule so the C2 and C3 positions are equivalent.
The strongest metabolite signals were doublets
(J¼ 37.3Hz) for malate C3 at 45.2 ppm and C2 at
73.1 ppm, in all six patients, indicating 2,3-13C2
malate. There was no discernable singlet for malate.
These results – malate doublets, but no singlets – indi-
cate that the malate was entirely derived, without
breaking the covalent bond between the two 13C
atoms, from the 2,3-13C2 succinate administered. A
singlet at 138.0 ppm for C2 and C3 of fumarate (indi-
cating 2,3-13C2 fumarate) was seen in all six patients.
This is a singlet because fumarate is a symmetrical mol-
ecule. Doublets (J¼ 36.8Hz) for lactate C3 (methyl
group) and for lactate C2 were observed in all six
patients, at 22.8 and 71.3 ppm, respectively, indicating
the presence of 2,3-13C2 lactate, together with singlets
for lactate C3 and C2.
Doublets (J¼ 34.8Hz) were observed at 57.4 and
30.4 ppm, representing glutamine C2 and C3, respect-
ively, indicating the presence of 2,3-13C2 glutamine in
ﬁve of six patients, together with singlets for glutamine
Figure 3. ISCUS clinical microdialysis analyser measurements. Results are during 24 h baseline perfusion (with plain unsupplemented
CNS perfusion fluid) and during 24 h perfusion with 2,3-13C2 succinate (disodium salt; 12mmol/L). Symbols joined by lines represent
individual patients (TBI Patients 1–9). Each pair of data-points indicates median levels at baseline and during succinate perfusion,
respectively, for that patient. Note that, for Patients 6 and 7, the lactate concentrations were similar (but not identical), so their
symbols and lines are very close to each other. For Patients 1 and 2, the baseline period was post-succinate, while for the other seven
patients, the baseline period was pre-succinate. Changes between baseline and succinate perfusion were significant for lactate/pyruvate
ratio (p¼ 0.0152), glucose (p¼ 0.038) and glutamate (p¼ 0.018) by Wilcoxon’s signed rank test.
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C2 and C3. The remaining patient (TBI Patient 1)
showed no clear doublet or singlet signals discernable
above noise for Gln C2 or Gln C3. Peak identities were
corroborated on NMR by two-dimensional 1H-13C
HSQC spectra. Glutamine is synthesised from glutam-
ate that is a spin-oﬀ from the TCA cycle intermediate
alpha-ketoglutarate. The presence of doublets for glu-
tamine C2 and C3 indicates metabolism of 2,3-13C2
succinate by the TCA cycle with the covalent bond
between the two 13C atoms intact. No other doublet
signals were observed for glutamine (or glutamate).
None of the six patients showed a clear glutamine C4
singlet above baseline noise. Quantiﬁcation of the C2
and C3 glutamine singlets (after subtracting back-
ground natural abundance 13C) revealed small degrees
of fractional enrichment with medians of 1.1% (0%–
3.6%) and 3.5% (1.1%–6.9%), respectively.
Pyruvate was undetectable in our 13C NMR spectra.
Pyruvate’s chemical shifts (C3 at 29.15 ppm, C2 at
207.7 ppm and C1 at 172.8 ppm, in spectra of stand-
ards) do not coincide with lactate or any other of our
analytes. Pyruvate is at the crossroads of several bio-
chemical pathways, being synthesised and consumed,
so its concentration is never high, and microdialysis
only samples the extracellular compartment. In the lit-
erature, 13C-labelled pyruvate is usually not itself
detectable as a metabolite in NMR spectra of brain
tissue extracts, and pyruvate’s involvement as an inter-
mediate is inferred from detection of labelling in its
products.28,29 Moreover, exogenous 13C-labelled pyru-
vate is very rapidly metabolised by brain.30
Results for fractional enrichment (%) in 2,3-13C2
glutamine are shown in Figure 5(a). The median was
16.2% (5.3%–22.6%) measured using the C3 doublet.
Similar fractional enrichment was seen for the glutam-
ine C2 doublet, as expected. The 13C doublet signals at
glutamine C2 and C3 were not background-subtracted
because the probability of two natural endogenous 13C
atoms occurring next to each other is 0.01%.
Fractional enrichment (%) results in 2,3-13C2 lactate
are shown in Figure 5(a). Median (IQR) fractional
enrichments of the lactate C3 and C2 doublets were
2.3% (1.1%–4.5%) and 2.0% (0.8%–4.4%).
The corresponding concentrations (in mmol/L) of
2,3-13C2 glutamine and 2,3-
13C2 lactate are shown in
Figure 5(b). Singlets for lactate C3 and C2 revealed
no signiﬁcant 13C enrichment above background nat-
ural abundance 13C. In ﬁve of six patients, enrichment
Figure 4. Illustrative examples of 13C NMR spectra. Upper two spectra are for microdialysates from TBI Patients 3 and 5 who
received perfusion with 2,3-13C2 succinate disodium salt (12mmol/L). For comparison, the 2,3-
13C2 succinate solution (before per-
fusion) (third spectrum) and microdialysate from an unlabelled TBI patient (using plain unsupplemented CNS perfusion fluid) (fourth
spectrum) are also shown. Glc: glucose; Lac: lactate; Gln: glutamine; Mal: malate; DSS: 4,4-dimethyl-4-silapentane-1-sulfonate sodium
salt (the internal reference standard). Spectra were run from 20 ppm toþ 250 ppm. The main reference DSS signal at 0 ppm, and
fumarate (138 ppm singlet for equivalent C2 and C3, in the spectra of patients with 2,3-13C2 succinate perfusion) are not shown in the
ranges illustrated.
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was greater in 2,3-13C2 glutamine than in 2,3-
13C2 lac-
tate, while in the remaining patient (TBI Patient 1),
2,3-13C2 glutamine was undetectable although 2,3-
13C2
lactate was present. The median (IQR) 2,3-13C2 lactate/
2,3-13C2 glutamine enrichment ratio was 19.9%
(12.9%–21.7%).
The 13C-labelling patterns identiﬁed are thus clear
evidence for the metabolic pathways shown in Figure 1.
Discussion
We have shown that 2,3-13C2 succinate (disodium salt)
perfused via microdialysis catheters in TBI patients
entered the TCA cycle evidenced by 13C-labelling pat-
terns in metabolites (Figures 1 and 4), and also poten-
tiated several aspects of brain chemistry: importantly
decreases in extracellular LPR and glutamate
concentration.
Figure 5. 13C enrichment in glutamine and lactate. (a) Fractional enrichment values (%) for microdialysate 2,3-13C2 glutamine (blue
bars; based on the glutamine C3 doublet signal) and 2,3-13C2 lactate (red bars; based on the lactate C3 doublet signal). (b)
Corresponding concentrations (mmol/L) of 2,3-13C2 glutamine and 2,3-
13C2 lactate.
8 Journal of Cerebral Blood Flow & Metabolism
Significance of double labelling patterns in
metabolites
The characteristic NMR doublets arising from two
adjacent 13C atoms prove cellular uptake and mito-
chondrial metabolism of 2,3-13C2 succinate revealing
downstream metabolites. Doublets are clearly distinct
from native endogenous molecules, because the prob-
ability of two endogenous 13C atoms being adjacent to
each other naturally is 0.01% (a 1 in 10,000 chance) and
indistinguishable from baseline ‘noise’ in these spectra.
As SDH is exclusively mitochondrial, downstream
metabolites of 2,3-13C2 succinate must be derived
from pathways stemming from mitochondrial metabol-
ism. In microdialysates, the extracellular concentrations
and 13C labelling patterns allow deduction of cellular
metabolic pathways. The doubly 13C-labelled metabol-
ites are unambiguous evidence the 2,3-13C2 succinate
molecules crossed from the perfusate into the brain
extracellular space, entered the cells and were metabo-
lised, exported into the extracellular ﬂuid and recovered
by the microdialysis catheter.
13C NMR clearly demonstrated that 2,3-13C2 malate,
2,3-13C2 glutamine and 2,3-
13C2 lactate were among the
metabolites, indicating TCA cycle metabolism with the
C2-C3 carbon–carbon bond intact (Figure 5). 2,3-13C2
glutamine is a TCA spinout product originating from
alpha-ketoglutarate, a TCA cycle intermediate exiting
as glutamate, enzymatically inter-convertible with glu-
tamine that predominates extracellularly.
The TCA cycle intermediate OAA can spin out
aspartate, which can exit mitochondria (via the glutam-
ate/aspartate carrier) via the malate-aspartate shuttle
mechanism.20 In the cytosol, aspartate is converted to
OAA and thence to malate, which can re-enter mito-
chondria (via the malate/alpha-ketoglutarate carrier).
The 2,3-13C2 malate detected in microdialysates may
have emerged from the TCA cycle via this pathway.
Our identiﬁcation of 2,3-13C2 lactate among the
metabolites of 2,3-13C2 succinate is the ﬁrst demonstra-
tion of the TCA cycle spin-out route of lactate produc-
tion in human TBI brain, and merits investigation.
Previous indications were in animal brains.28,29,31 The
TCA cycle intermediates malate and OAA can be con-
verted to pyruvate by malic enzyme (ME); also OAA
can be converted by phosphoenolpyruvate carboxyki-
nase (PEPCK) plus pyruvate kinase (PK) to pyruvate,
which LDH can convert to lactate. Our ﬁnding of TCA
cycle-derived lactate may have implications for inter-
preting high extracellular levels of lactate and LPR,
hitherto simply attributed to glycolysis. An LPR> 25
is interpreted as either hypoxia or ‘mitochondrial dys-
function’. The latter remains poorly understood, and
this study raises questions of whether the lactate (and
implicitly pyruvate) derived from TCA-cycle spin-out,
termed cataplerosis31 forms a signiﬁcant proportion of
total extracellular lactate (and pyruvate), whether cat-
aplerotic levels change in injured vs. normal brain, and
biological implications.
Pyruvate recycling – Partial versus full
Lactate generation by TCA cycle cataplerosis is also
termed ‘partial pyruvate recycling’, as the pyruvate
spun out from the TCA cycle does not re-enter it but
proceeds to lactate that exits from cells.31 This appears
distinct from full pyruvate recycling28,32,33 whereby
spun-out pyruvate is converted by pyruvate dehydro-
genase (PDH) to acetate that re-enters the TCA cycle.
We found no evidence for full recycling, as spun-out
2,3-13C2 pyruvate conversion by PDH to 1,2-
13C2 acet-
ate entering the TCA cycle would have produced
4,5-13C2 glutamine,
32 which we did not detect. Neither
did we detect 1,2-13C2 lactate, which would have
resulted from subsequent spin-out from 1,2-13C2 oxa-
loacetate, and there was no signiﬁcant enrichment for
3-13C lactate, which would have arisen from spin-out
from 3,4-13C2 oxaloacetate.
Re-entry of 2,3-13C2 pyruvate via anaplerotic path-
ways pyruvate carboxylase (PC) or ME into the TCA
cycle would produce 2,3-13C2 glutamine, the same
13C-pattern as if 2,3-13C2 succinate metabolism pro-
ceeds directly (without exit of intermediates and
re-entry) round the TCA cycle to 2,3-13C2 alpha-
ketoglutarate and spins out 2,3-13C2 glutamine.
Re-entry via PC or ME seems unlikely in the absence
of evidence for re-entry via PDH. Therefore, the 2,3-13C2
glutamine detected is probably from 2,3-13C2 succinate
metabolism proceeding directly round the TCA cycle,
further supported by fractional enrichment (%) for
13C being greater (in ﬁve of six patients) in 2,3-13C2 glu-
tamine than in 2,3-13C2 lactate (Figure 5(a)).
Succinate perfusion potentiates local brain chemistry
Conventional measures (regardless of labelling), on an
ISCUS microdialysis analyser, at baseline and during
2,3-13C2 succinate perfusion, showed glucose concen-
tration decrease suggesting greater utilisation, a lower
LPR due to relatively raised pyruvate, and glutamate
decrease. LPR ‘Type 2’ elevation characterised by low
pyruvate without hypoxia or ischaemia is attributed to
metabolic disturbance.34 Increasing pyruvate and
thereby lowering LPR thus concurs with better brain
metabolism, consistent with TCA cycle operation indi-
cated by the 13C-labelling patterns.
To generate 1mole of pyruvate by glycolysis, 1mole
of NADþ is converted into NADH, which must be
recycled (oxidised) back to NADþ to sustain glycolysis.
Recycling can occur by the mitochondrial ETCs
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(if operational). NADH cannot cross the mitochondrial
membrane, so hydrogens and electrons are transferred
indirectly by shuttles (malate-aspartate and/or glycerol
3-phosphate).20 Malate-aspartate shuttle operation
concurs with 2,3-13C2 malate in microdialysates. In
mitochondrial dysfunction or hypoxia, NADH can be
recycled to NADþ by LDH-mediated conversion of
pyruvate to lactate in the cytosol, producing a high
extracellular LPR.
Lowering of brain extracellular glucose during suc-
cinate perfusion, suggesting improved glucose utilisa-
tion, together with a lower extracellular LPR, may
stem from better redox behaviour by aforementioned
NADH to NADþ recycling by mitochondrial shut-
tles,20 lessening LDH-mediated conversion of pyruvate
to lactate. The lower extracellular glutamate during
succinate perfusion may result from the malate-aspar-
tate shuttle, drawing glutamate into mitochondria for
consumption via the TCA cycle, preventing excitotoxic
glutamate build-up. High extracellular glutamate and
glucose levels are associated with adverse clinical
outcomes.3
Conventionally, the microdialysis literature ascribes
glycerol increase to phospholipid degradation suggest-
ing cell death.35 However, debate exists34–36 because
glycerol is a glucose metabolite37–39 and glycerol
increase during succinate perfusion may arise from
increased glycolysis. Glycerol decreased after succinate
perfusion ceased, in the two patients whose baseline
period was post-succinate (Figure 3), concurring with
metabolically derived glycerol, rather than cell death.
Conceivably, glycerol may increase by succinate fuelling
the mitochondrial ETC enhancing the glycerol 3-phos-
phate (G3P) shuttle, recycling NADH to NADþ in the
cytosol when dihydroxyacetone phosphate (DHAP; a
glycolysis intermediate) is reduced by cytosolic glycerol
3-phosphate dehydrogenase (GPDH) to G3P.20 This is
re-oxidized to DHAP by mitochondrial GPDH and
electrons transferred to CoQ and enter the mitochon-
drial ETC.20 Like the malate-aspartate shuttle (above),
enhancing the G3P shuttle would improve recycling of
NADH to NADþ by mitochondrial ETC, giving lower
LPR and more eﬃcient glucose utilisation.
Importance of oxygen
PbtO2 measurements indicated oxygen supply to the
region that received disodium succinate. Without
oxygen, the mitochondrial ETC cannot function prop-
erly. In experimental ischaemia, SDH (ETC complex II
and part of the TCA cycle) ran ‘backwards’, building
up succinate and reverse electron transport to complex
I.40 Reperfusion produced a surge in reactive oxy-
gen species (via complex I) and cell death.40
Dimethyl succinate (an artiﬁcial, lipophilic derivative
much more taken up by cells than disodium succinate)
exacerbated ischaemia–reperfusion damage, while mal-
onate, a TCA cycle inhibitor that blocks SDH, pro-
tected against ischaemia–reperfusion injury.40 Our
present study did not involve ischaemia–reperfusion.
We suggest that using succinate to support mitochon-
drial metabolism should be performed in the presence
of adequate oxygenation, not ischaemia–reperfusion.
In circumstances like our study, where oxygen
appears not limiting, oxidative phosphorylation is lim-
ited by mitochondrial eﬃciency, which appears
improved (lower microdialysate LPR) by succinate
administration. The doubly 13C-labelled metabolites
unambiguously prove that the disodium 2,3-13C2 suc-
cinate was taken up and metabolised by mitochondria.
Limitations
The reason we combined brain microdialysates for 24 h
per patient was to provide enough material for 13C
NMR within a workable spectrum acquisition time
on the NMR spectrometer. Our 500MHz NMR spec-
trometer has a cryoprobe21,22 that is more sensitive
than non-cryo probe technology, but, nevertheless,
limits how short a microdialysis timeframe we can ana-
lyse. NMR micro-cryoprobes are commercially avail-
able, for smaller samples, and future adoption, with
higher-ﬁeld NMR spectrometers for even greater sensi-
tivity, if accessible, will improve time-resolution for
tracking biochemical pathways. We did not analyse
blood. Focal brain micro-dosing is unlikely to yield
measurable labelling in blood, due to dilution of
13C-labelled species with unlabelled endogenous species
and physical volume of blood. Neurocritical care pro-
tocol-driven therapy includes maintaining a serum glu-
cose 4–7mmol/L target range. While serum glucose and
glycaemic control can inﬂuence brain glucose, this rela-
tionship is not necessarily straightforward and may be
lost in injured brain,27,41 meriting dedicated study with
continuous monitoring of both blood and brain.
Cerebral microdialysis is an invasive technique and
is thus eﬀectively limited to patients being monitored
following severe brain injury. These patients are
sedated (see ‘Patients and methods’ section), so there
is no placebo eﬀect – they are unconscious. On account
of its invasive nature, there are no truly normal controls
for cerebral microdialysis in humans. It has sometimes
been possible to perform microdialysis in radiologically
normal brain areas in patients undergoing surgery for
removal of benign tumours in a diﬀerent part of the
brain,22,42 but patient considerations and practical mat-
ters make such sampling rare. In the present study, we
used each TBI patient as his or her own control (see
‘Patients and methods’ and ‘Results’ sections).
In further support of this approach, it has been noted
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in the literature that microdialysis data are highly auto-
correlated even at up to a future 30 h, and subject iden-
tity alone explains 52% to 75% of microdialysis marker
variance, determined in a large study (comprising more
than 7350 hourly samples of complete microdialysis sets
from 90 TBI patients) using statistical and pattern-
recognition computer models.24 Thus, microdialysate
data are highly individualised and it was therefore logi-
cal to use each patient as his/her own control rather
than comparing with a separate control group of dif-
ferent TBI patients.
Mitochondrial dysfunction is deﬁned as an inability
to generate energy despite ‘adequate’ provision of meta-
bolic fuels and oxygen. This suggests a fundamental
biochemical failure at the mitochondrial level following
TBI. Mitochondrial dysfunction is undoubtedly a com-
plex phenotype and exploring its full ramiﬁcations is
outside the scope of the present study. We have estab-
lished that TBI brain retains suﬃcient mitochondrial
capability to metabolise exogenous succinate by the
TCA cycle, proved using double 13C-labelling. This
exogenous fuelling of the TCA cycle resulted in appar-
ent improvements in brain chemistry judged by surro-
gate endpoints including LPR decrease. Whether such
changes would translate to better clinical outcome
would need a more extensive, larger study in TBI
patients. Further support for beneﬁts of augmenting
brain mitochondrial oxidative metabolism comes from
studies in rats with methylene blue,43 or with kaemp-
ferol,44 which enhances mitochondrial matrix uptake
of Ca2þ and boosts oxidative metabolism, which led
to improved brain function and behavioural outcomes
after experimental brain injury in a rat TBI model.45
Conclusion
Here we have shown that 2,3-13C2 succinate delivered
by microdialysis can interrogate the TCA cycle’s role in
producing 13C-labelled metabolites exported into the
interstitium, proof-of-concept that the TCA cycle can
be directly supplemented and TBI brain chemistry
potentiated. Our novel discovery of the TCA cycle as
a source of lactate in human TBI brain calls for revision
of lactate’s signiﬁcance, hitherto regarded as simply
glycolytic, with possible implications for other diseases
(e.g. cancer). Lower LPR suggests that succinate
improves redox balance, conceivably by boosting shut-
tles utilising mitochondrial ETCs to recycle NAPH to
NADþ, possibly promoting glucose utilisation and glu-
tamate clearance from the interstitium. Whether such
metabolic shifts would ameliorate ATP generation
merits investigation. Speciﬁc intervention that modiﬁes
the LPR provides a promising future avenue.27
This study opens the prospect of enhancing mitochon-
drial metabolism by using TCA cycle products/
substrates such as succinate or other species as a poten-
tial therapeutic strategy, for brain injury and other
neurological disorders involving mitochondrial
dysfunction.
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